Bruce Torkan, MD
General Practice · Los Angeles, CANPI 1699770321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$749
- GSK$730
- Sunovion Pharmaceuticals Inc.$722
- Lilly USA, LLC$663
- Novo Nordisk$574
- plus $4K from 30 others
Across 173 payments — averaging $21,852 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$981K
- Eli Lilly$898K
- E.r. Squibb & Sons, L.L.C.$456K
- Gilead$380K
- Adamis Pharmaceuticals Corporation$279K
- Taro Pharmaceuticals USA, Inc.$242K
- plus $545K from 9 others
What the payments were for
- Food & beverage$9,65299%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $2,108 |
| AstraZeneca | 21 | $749 |
| GSK | 26 | $730 |
| Sunovion Pharmaceuticals Inc. | 67 | $722 |
| Lilly USA, LLC | 29 | $663 |
| Novo Nordisk | 9 | $574 |
| Sumitomo Pharma America, Inc. | 33 | $508 |
| Biohaven Pharmaceuticals, Inc. | 10 | $392 |
| Amgen | 22 | $370 |
| Pfizer | 14 | $305 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $263 |
| Astellas Pharma US Inc | 4 | $254 |
| Xeris Pharmaceuticals, Inc. | 5 | $216 |
| Sanofi Pasteur Inc. | 6 | $210 |
| Merck | 6 | $189 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $184 |
| Madrigal Pharmaceuticals | 2 | $156 |
| E.r. Squibb & Sons, L.L.C. | 4 | $152 |
| Phathom Pharmaceuticals, Inc. | 2 | $152 |
| Ardelyx, Inc. | 5 | $142 |
| Scilex Pharmaceuticals Inc. | 5 | $100 |
| Bristol Myers Squibb | 1 | $97 |
| Boehringer Ingelheim | 4 | $88 |
| Aimmune Therapeutics, Inc. | 3 | $69 |
| Ironwood Pharmaceuticals, Inc | 3 | $57 |
| Shield Therapeutics Inc | 2 | $53 |
| Bayer | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $43 |
| Cranial Technologies, Inc | 2 | $32 |
| Radius Health, Inc. | 1 | $29 |
| Insmed, Inc. | 1 | $25 |
| Mannkind Corporation | 1 | $18 |
| Vertex | 1 | $18 |
| Verrica Pharmaceuticals Inc. | 1 | $17 |
| Ascend Therapeutics US, LLC | 1 | $12 |
| Romark Laboratories, LC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,747 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 111 | $69,850 |
| JanuviaSitagliptin Phosphate | 90 | $65,302 |
| JardianceEmpagliflozin | 86 | $55,297 |
| FarxigaDapagliflozin Propanediol | 51 | $34,030 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $27,312 |
| VascepaIcosapent Ethyl | 69 | $23,809 |
| TrulicityDulaglutide | 22 | $21,643 |
| Misoprostol | 503 | $21,087 |
| EliquisApixaban | 35 | $20,327 |
| LinzessLinaclotide | 25 | $16,588 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 395 | $14,599 |
| Icosapent Ethyl | 80 | $13,824 |
| EntrestoSacubitril/Valsartan | 16 | $13,153 |
| MyrbetriqMirabegron | 16 | $6,881 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $6,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $189 | $72,147105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $508 | $69,850111 claims |
| Boehringer IngelheimJardiance | $88 | $55,29786 claims |
| AstraZenecaFarxiga | $749 | $34,03051 claims |
| GSKTrelegy Ellipta | $730 | $27,31243 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $663 | $26,42546 claims |
| PfizerEliquis | $305 | $20,32735 claims |
| AbbVieLinzess | $2,108 | $16,58825 claims |
| Astellas Pharma US IncMyrbetriq | $254 | $6,88116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Los Angeles
- Abdi SameniLos Angeles$316K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Richard KimLos Angeles$97K
- Michael SchneiderLos Angeles$53K
- Ronald JeffersonLos Angeles$45K
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.